|Videos|January 26, 2022
Urology Times 50 Innovations Series: Tissue engineering and regenerative medicine
Author(s)Urology Times staff
"These are fairly new technologies, but they've already made a dent into patient care," says Anthony Atala, MD.
Advertisement
As part of the Urology Times' 50th Anniversary Innovation Celebration, Anthony Atala, MD, discusses how tissue engineering and regenerative medicine have greatly impacted the field of urology over the past 50 years. Atala is a director of the Wake Forest Institute for Regenerative Medicine, and the W. Boyce Professor and Chair of Urology at Wake Forest University in Winston-Salem, North Carolina.
Advertisement
Related to this article
William Huang, MD, discusses histotripsy for renal tumors, the #HOPE4KIDNEY trial, and the technology’s potential to preserve kidney function.
Systemic therapy now anchors MIBC care and expands bladder preservation options, according to Joshua J. Meeks, MD, PhD.
BCG optimization should precede checkpoint inhibitor intensification in BCG-naive high-risk NMIBC, according to Tom Jayram, MD.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
The phase 1 study is intended to characterize the safety, tolerability, and feasibility of intravesical administration of UGN-501.
Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how work force gaps may affect comprehensive infertility evaluations.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Advertisement
Advertisement
Trending on Urology Times
1
Treating MIBC as a systemic disease reshapes bladder preservation
2
Alicia Morgans, MD, discusses cognitive outcomes with darolutamide vs enzalutamide
3
UGN-501 enters phase 1 testing for recurrent non–muscle invasive bladder cancer
4
Infertility care: Examining geographic gaps in access
5